Cyld Inhibits Tumor Cell Proliferation by Blocking Bcl-3-Dependent NF-κB Signaling

Cell

Volumn 125, Issue 4, 2006, Pages 665-677

  Massoumi, Ramin ^a   Chmielarska, Katarzyna ^a   Hennecke, Katharina ^b   Pfeifer, Alexander ^b   Fässler, Reinhard ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BCL 3; PROTEIN P50; PROTEIN P52; SYNAPTOTAGMIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYLD GENE; EMBRYO; FEMALE; GENE LOCATION; HUMAN; HUMAN TISSUE; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ULTRAVIOLET RADIATION;

ANIMALIA;

EID: 33646531810     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.03.041     Document Type: Article

References (40)

1. Bignell G.R., Warren W., Seal S., Takahashi M., Rapley E., Barfoot R., Green H., Brown C., Biggs P.J., Lakhani S.R., et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25 (2000) 160-165
2. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., and Siebenlist U. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72 (1993) 729-739
3. Brasier A.R., Lu M., Hai T., Lu Y., and Boldogh I. NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence. J. Biol. Chem. 276 (2001) 32080-32093
4. Brummelkamp T.R., Nijman S.M., Dirac A.M., and Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424 (2003) 797-801
5. Budunova I.V., Perez P., Vaden V.R., Spiegelman V.S., Slaga T.J., and Jorcano J.L. Increased expression of p50-NF-κB and constitutive activation of NF-κB transcription factors during mouse skin carcinogenesis. Oncogene 18 (1999) 7423-7431
6. Cogswell P.C., Guttridge D.C., Funkhouser W.K., and Baldwin Jr. A.S. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 19 (2000) 1123-1131
7. Fujita T., Nolan G.P., Liou H.C., Scott M.L., and Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev. 7 (1993) 1354-1363
8. Ghosh S., and Karin M. Missing pieces in the NF-κB puzzle. Cell 109 (2002) 81-96
9. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Baldwin Jr. A.S. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19 (1999) 5785-5799
10. Hashimoto K., Mori N., Tamesa T., Okada T., Kawauchi S., Oga A., Furuya T., Tangoku A., Oka M., and Sasaki K. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod. Pathol. 17 (2004) 617-622
11. Hinz M., and Strauss M. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19 (1999) 2690-2698
12. Hirai Y., Kawamata Y., Takeshima N., Furuta R., Kitagawa T., Kawaguchi T., Hasumi K., Sugai S., and Noda T. Conventional and array-based comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix. Int. J. Oncol. 24 (2004) 977-986
13. Israel A. The IKK complex: an integrator of all signals that activate NF-κB?. Trends Cell Biol. 10 (2000) 129-133
14. Joyce D., Albanese C., Steer J., Fu M., Bouzahzah B., and Pestell R.G. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 1 (2001) 73-90
15. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
16. Kollisch G., Kalali B.N., Voelcker V., Wallich R., Behrendt H., Ring J., Bauer S., Jakob T., Mempel M., and Ollert M. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114 (2005) 531-541
17. Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., and Courtois G. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424 (2003) 801-805
18. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 4 (2003) 339-345
19. McKeithan T.W., Ohno H., and Diaz M.O. Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia. Genes Chromosomes Cancer 1 (1990) 247-255
20. Mempel M., Voelcker V., Kollisch G., Plank C., Rad R., Gerhard M., Schnopp C., Fraunberger P., Walli A.K., Ring J., et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J. Invest. Dermatol. 121 (2003) 1389-1396
21. Nishikori M., Maesako Y., Ueda C., Kurata M., Uchiyama T., and Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 101 (2003) 2789-2796
22. Nolan G.P., Fujita T., Bhatia K., Huppi C., Liou H.C., Scott M.L., and Baltimore D. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol. Cell. Biol. 13 (1993) 3557-3566
23. Pfeifer A., Kessler T., Silletti S., Cheresh D.A., and Verma I.M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. USA 97 (2000) 12227-12232
24. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70 (2001) 503-533
25. Plafker S.M., Plafker K.S., Weissman A.M., and Macara I.G. Ubiquitin charging of human class III ubiquitin-conjugating enzymes triggers their nuclear import. J. Cell Biol. 167 (2004) 649-659
26. Quintanilla M., Brown K., Ramsden M., and Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322 (1986) 78-80
27. Regamey A., Hohl D., Liu J.W., Roger T., Kogerman P., Toftgard R., and Huber M. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J. Exp. Med. 198 (2003) 1959-1964
28. Rocha S., Martin A.M., Meek D.W., and Perkins N.D. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol. Cell. Biol. 23 (2003) 4713-4727
29. Romero M.R., Carroll J.M., and Watt F.M. Analysis of cultured keratinocytes from a transgenic mouse model of psoriasis: effects of suprabasal integrin expression on keratinocyte adhesion, proliferation and terminal differentiation. Exp. Dermatol. 8 (1999) 53-67
30. Seitz C.S., Lin Q., Deng H., and Khavari P.A. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB. Proc. Natl. Acad. Sci. USA 95 (1998) 2307-2312
31. Strobel P., Zettl A., Ren Z., Starostik P., Riedmiller H., Storkel S., Muller-Hermelink H.K., and Marx A. Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm. Am. J. Surg. Pathol. 26 (2002) 119-124
32. Thornburg N.J., Pathmanathan R., and Raab-Traub N. Activation of nuclear factor-κB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 63 (2003) 8293-8301
33. Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., and Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424 (2003) 793-796
34. van Balkom I.D., and Hennekam R.C. Dermal eccrine cylindromatosis. J. Med. Genet. 31 (1994) 321-324
35. Watanabe N., Iwamura T., Shinoda T., and Fu T. Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-κB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. EMBO J. 16 (1997) 3609-3620
36. Weissman A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2 (2001) 169-178
37. Westerheide S.D., Mayo M.W., Anest V., Hanson J.L., and Baldwin Jr. A.S. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol. Cell. Biol. 21 (2001) 8428-8436
38. Wilkinson M.G., and Millar J.B. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J. 14 (2000) 2147-2157
39. Zhang M.Y., Harhaj E.W., Bell L., Sun S.C., and Miller B.A. Bcl-3 expression and nuclear translocation are induced by granulocyte-macrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors. Blood 92 (1998) 1225-1234
40. Zhang Q., Didonato J.A., Karin M., and McKeithan T.W. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins. Mol. Cell. Biol. 14 (1994) 3915-3926